** Shares of Telix Pharmaceuticals TLX.AX fall 6% to A$26.86, their lowest since April 14
** Stock among the biggest percentage losers in the benchmark ASX200 index .AXJO
** Biotech firm says that the U.S. Food and Drug Administration (FDA) has refused to approve its new drug application for Pixclara, an investigational agent for imaging glioma
** FDA has requested additional clinical evidence to progress the application, stating that the application cannot be approved in its current form - TLX
** Stock fell as much as 9.3% earlier in the day, marking its worst intraday drop since April 7
** Stock up 9.7% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。